EULAR Madrid is off to a great start. Madrid is not too hot compared to two years ago. Beautiful region to explore. Do you know where this castle from 12th c that inspired Disney castle is? @RheumNow #EULAR2019 pic.twitter.com/N2znTe3EFW
— Janet Pope (@Janetbirdope) June 12, 2019
Reunite with old friends and extend your professional network at the #EULAR2019 Networking Platform in Hall 6. We hope you are enjoying your evening! pic.twitter.com/zcqx9wHSmU
— EULAR (@eular_org) June 12, 2019
— Dr. Dinesh Khanna (@sclerodermaUM) June 12, 2019
impact on mRSS in abatacept group whereas placebo did change (purple lines). Time for personalized medicine!! #EULAR2019 pic.twitter.com/XmYLq8ddIp
— Dr. Dinesh Khanna (@sclerodermaUM) June 12, 2019
Early SSC is very hetogeneous disease. Data from the ASSET trial @bmsnews @UMIntMed and Whitfield lab (funded by @NIAIDNews) shows 1. Skin gene expression can largely be divided into 3 large groups with 41% with Normal like expression!! 2. Patients RX with abatacept had striking
— Dr. Dinesh Khanna (@sclerodermaUM) June 12, 2019
We don’t take medications either because we can’t or because we don’t want to. Robert Horne on #adherence #EULAR2019 pic.twitter.com/YUdLCfGErV
— Loreto Carmona 🖖 (@carmona_loreto) June 12, 2019
We need to talk about repeated ANAs – good lessons from the plenary hall today about 7875 repeated ANA tests from a single center. #EULAR2019 OP0020 by Ai Li Yeo @RheumNow @MonashHealth @earlyARA @ChooseWiselyAU pic.twitter.com/j00DDKuZFt
— David Liew (@drdavidliew) June 12, 2019
This was a great presentation – 36K ANA test, 7875 repeat ANAs (11% rheums 82% non-rheums) ~10% each went from Pos to Neg (or Neg to Pos) but only 5 new Rheumatic Dx made – incredibly low yield and low PPV https://t.co/Ng8Fg4k158
— Dr. John Cush (@RheumNow) June 12, 2019
Tildrakizumab, an IL-12/p19 inhibitor, studied in 391 very active #PsA pts. Rx compared PBO vs 4 different doses and TIL showed superior ACR 20/50/70 responses (79.5%/52.6%/29.1% vs 24%PBO) and 80% PASI75 at wk24. #EULAR2019 LB0002 pic.twitter.com/QKg0yDS28B
— Dr. John Cush (@RheumNow) June 12, 2019
I am so sorry to be missing EULAR this yr but feeling better!!! Will be Skyping in to the satellite Friday discussing what really matters to patients!!! @CCalabreseDO @RheumNow #IL6 @arthdoc https://t.co/teXkmmeAuo
— Leonard Calabrese (@LCalabreseDO) June 12, 2019
Turned up to #EULAR2019 and immediately ran into three other Australians (separately). We’re all over this joint! @dr_rachelblack @tuna0sashimi 🇦🇺🇦🇺 @RheumNow pic.twitter.com/kM7IHKQykf
— David Liew (@drdavidliew) June 12, 2019
Dr Jon Kay on “drift” of reference product. Lessons from Herceptin biosimilar development #eular2019 SP0014 pic.twitter.com/uqWgYESe6N
— Dr. John Cush (@RheumNow) June 12, 2019
DESIR 708 early TNFi naive axSpA finds only 36% started a TNFi & 49% switched to a 2nd TNFi & 47% to 3rd TNFi #EULAR2019 OP0012 pic.twitter.com/5TMPofwRas
— Dr. John Cush (@RheumNow) June 12, 2019
What happens when MTX-IR pts who don't respond to Adalimumab or Upadacitinib in Select compare RCT switch to other treatment? More switched out of adalimumab. Either group on average did well maybe switch to Upa a bit better but post hoc analysis. OP0029 #EULAR2019 @RheumNow pic.twitter.com/sIG0kPPfNB
— Janet Pope (@Janetbirdope) June 12, 2019
Ustekinumab in SLE, SLEDAI >=6 bilag 1A or 2B, ph2 results SRI-4 at w24 published. Sustained responses acc to SRI4, PGA, joint and CLASI to w48. Clasi even had higher response at w48. Those which switched to open label showed incremental improvement. Nice. #eular2019 @RheumNow
— Alberta Hoi (@tuna0sashimi) June 12, 2019
In a disease where there aren’t a lot of options, nintedanib reduces FVC rate of decline in SSc-ILD by >40%, independently of SSc subtype, antibody status, MMF exposure, just like it does in IPF.
Breathtaking results (so to speak) #EULAR2019 Distler for SENSCIS OP0017 @RheumNow https://t.co/eRsMxc7sdr pic.twitter.com/LyqQf5apfx
— David Liew (@drdavidliew) June 12, 2019
Difficult to use existing “borrowed” conventional measures or essdai to measure change in the joint domain (most commonly affected) in abatacept study on primary Sjogren #eular2019 @RheumNow
— Alberta Hoi (@tuna0sashimi) June 12, 2019
Disappointing @tuna0sashimi: BMS abatacept 125mg wkly in Sjogren: essdai >=5 SSA+ primarily outcome mean change in essdai. Day 169 onwards open label. Negative study using these endpoints but some positive effect on serum IgG and complements. #eular2019 @RheumNow
— Dr Irwin Lim (@_connectedcare) June 12, 2019
Fantastic talk by Georgios Filippou highlighting how we can use US to help us differentiate DDx and clinical phenotypes. #eular2019 @RheumNow pic.twitter.com/hxKqrziDSN
— Alberta Hoi (@tuna0sashimi) June 12, 2019